BOSTON, Dec. 20, 2024 /PRNewswire/ -- Medicilon, a leading preclinical contract research organization (CRO), has named Dr. Lilly Xu as its new Chief Technology Officer (CTO). With over 30 years of experience in preclinical drug development, Dr. Xu will lead Medicilon's technological innovation and global expansion, strengthening its capabilities to deliver cutting-edge R&D solutions.
Dr. Xu, who holds a Ph.D. in Biology from St Louis University, is a recognized expert in pharmacokinetics, toxicology, and drug metabolism. She has successfully led numerous global drug development programs from early discovery through clinical stages and held leadership roles at major pharmaceutical and biotech companies, including Pharmaron, Icagen, Purdue Pharma, Sanofi, and Amgen.
"We are thrilled to welcome Dr. Xu during this pivotal time in Medicilon's growth," said Dr. Chunlin Chen, Founder and CEO of Medicilon. "Her extensive expertise and global perspective align with our vision of driving innovation and advancing our international presence."
Dr. Xu added, "I'm honored to join Medicilon's forward-thinking team. I look forward to contributing to platform innovation, accelerating the transition of research into clinical breakthroughs, and achieving milestones that will benefit our global clients and their patients."
Medicilon continues to expand its advanced research platforms, including nucleic acids, ADCs, PROTACs, antibodies, and cell and gene therapies, reinforcing its position as a leader in preclinical drug development.
Website: https://www.medicilon.com/
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer
SEOUL, South Korea, Dec. 20, 2024 /PRNewswire/ -- Air Premia, Korea's leading hybrid carrier, today announced the addition of its sixth Boeing 787-9 Dreamliner, marking its first fleet expansion in over 18 months. The airline also revealed plans to add three more aircraft in 2025.
As Korea's sole hybrid service carrier (HSC), Air Premia delivers premium services focusing on essential amenities at competitive prices, adhering to its philosophy of being "an airline loved for its premium yet essential services."
Aircraft Features and Configuration The new Boeing 787-9 Dreamliner features a 344-seat configuration, with 35 premium economy seats offering 46-inch seat pitch and 309 economy seats with 31-inch seat pitch. As part of the airline's fleet expansion, economy class seats will be upgraded to provide 33 inches of pitch.
Currently undergoing inspection and interior upgrades, the aircraft will begin commercial operations in January 2025, primarily serving routes to the Americas. The Boeing 787-9's fuselage, constructed with over 50% carbon composite materials, delivers 20% better fuel efficiency compared to conventional passenger aircraft. With a range of over 15,000 km, it efficiently serves long-haul routes such as Seoul to New York.
Network Expansion and Growth Strategy Air Premia currently operates scheduled flights to Los Angeles, New York, San Francisco, Tokyo Narita, and Bangkok. The carrier plans to launch new routes to Da Nang and Hong Kong in early 2025, followed by services to Honolulu and Seattle.
To support its network expansion, Air Premia will add three more aircraft in 2025, bringing its total fleet to nine by year-end.
"Fleet expansion is crucial for growth in the aviation industry," said Seung-shin Park, Head of Public Relations at Air Premia. "We are developing a balanced route portfolio to enhance both customer convenience and profitability."
To book your flight or learn more about Air Premia, please visit https://www.airpremia.com/kr/en.
For media inquiries and interview requests, please contact Seung-shin Park, ss.park@airpremia.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Air Premia Expands Fleet with 6th Boeing 787-9 Dreamliner, Plans New Routes for 2025
Air Premia Expands Fleet with 6th Boeing 787-9 Dreamliner, Plans New Routes for 2025
